Source:http://linkedlifedata.com/resource/pubmed/id/18310135
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2008-4-8
|
pubmed:abstractText |
Omiganan pentahydrochloride is a cidal cationic peptide with a broad antimicrobial spectrum, including yeast, currently in development as a topical agent for the prevention of catheter-associated infections. We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1460-2091
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
61
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1092-8
|
pubmed:meshHeading | |
pubmed:year |
2008
|
pubmed:articleTitle |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.
|
pubmed:affiliation |
JMI Laboratories, North Liberty, IA 52317, USA. thomas-fritsche@jmilabs.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|